Literature DB >> 1362704

A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets.

J W Kebabian1, D R Britton, M P DeNinno, R Perner, L Smith, P Jenner, R Schoenleber, M Williams.   

Abstract

A-77636, ((1R,3S) 3-(1'-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benz opyran hydrochloride), is a selective dopamine D1 receptor agonist. In a battery of receptor binding assays, A-77636 shows the highest affinity (pKi = 7.40 +/- 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 is an agonist at the dopamine D1 receptors in the fish retina (pEC50 = 8.13; EC50 = 1.1 nM; intrinsic activity = 102% of dopamine) and the rat caudate-putamen (pEC50 = 8.97; intrinsic activity = 134% of dopamine). The compound is functionally inactive at dopamine D2 receptors (EC50 > 10 microM). In rats with unilateral 6-OHDA (6-hydroxydopamine) lesions of the nigro-striatal dopaminergic pathway, A-77636 elicits prolonged (> 20 h) contralateral turning that is blocked by SCH 23390, a D1 receptor antagonist, but not by haloperidol at doses selective for the dopamine D2 receptor. Higher doses of A-77636 produce forelimb clonus in rats and mice. When tested in marmosets treated with MPTP to induce a parkinsonian-like state, A-77636 increases locomotor activity and decreases the severity of the parkinsonian-like symptoms: the compound is active after either subcutaneous or oral administration. A-77641, the optical antipode of A-77636, has a lower affinity towards the dopamine D1 receptor (pKi = 5.14, Ki = 7200 nM), is less potent as a dopamine D1 receptor agonist (pEC50 = 5.65; EC50 = 2200 nM), fails to elicit turning in the 6-OHDA-lesioned rat, and lacks antiparkinsonian efficacy in the MPTP-treated marmoset.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362704     DOI: 10.1016/0014-2999(92)90556-j

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Authors:  Jessica P Ryman-Rasmussen; Adam Griffith; Scott Oloff; Nagarajan Vaidehi; Justin T Brown; William A Goddard; Richard B Mailman
Journal:  Neuropharmacology       Date:  2006-10-24       Impact factor: 5.250

3.  D1 receptors in the nucleus accumbens-shell, but not the core, are involved in mediating ethanol-seeking behavior of alcohol-preferring (P) rats.

Authors:  S R Hauser; G A Deehan; R Dhaher; C P Knight; J A Wilden; W J McBride; Z A Rodd
Journal:  Neuroscience       Date:  2015-03-24       Impact factor: 3.590

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

5.  The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.

Authors:  S A Treseder; M Jackson; P Jenner
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.

Authors:  Danielle L Graham; Regis Hoppenot; April Hendryx; David W Self
Journal:  Psychopharmacology (Berl)       Date:  2006-07-12       Impact factor: 4.530

7.  Identification of RanBP 9/10 as interacting partners for protein kinase C (PKC) gamma/delta and the D1 dopamine receptor: regulation of PKC-mediated receptor phosphorylation.

Authors:  Elizabeth B Rex; Michele L Rankin; Yu Yang; Quansheng Lu; Charles R Gerfen; Pedro A Jose; David R Sibley
Journal:  Mol Pharmacol       Date:  2010-04-15       Impact factor: 4.436

Review 8.  Brain dopamine receptors: 20 years of progress.

Authors:  J W Kebabian
Journal:  Neurochem Res       Date:  1993-01       Impact factor: 3.996

9.  Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.

Authors:  Rouba Kozak; Tamás Kiss; Keith Dlugolenski; David E Johnson; Roxanne R Gorczyca; Kyle Kuszpit; Brian D Harvey; Polina Stolyar; Stacey J Sukoff Rizzo; William E Hoffmann; Dmitri Volfson; Mihaly Hajós; Jennifer E Davoren; Amanda L Abbott; Graham V Williams; Stacy A Castner; David L Gray
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

10.  Chronic lithium attenuates dopamine D1-receptor mediated increases in acetylcholine release in rat frontal cortex.

Authors:  E Acquas; H C Fibiger
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.